COVID-19 and the neurological disease therapeutic pipeline.

Jicha, Gregory A; Abner, Erin L

Jicha, Gregory A; Abner, Erin L.

Jicha GA; Department of Neurology, University of Kentucky College of Medicine, Lexington, KY, US. gajich2@email.uky.edu.
Abner EL; The Sanders-Brown Center on Aging, University of Kentucky College of Medicine, Lexington, KY, US. gajich2@email.uky.edu.

Nat Rev Neurol ; 17(2): 71-72, 2021 02.

Article in English | MEDLINE | ID: covidwho-989871

Subject(s)

COVID-19/prevention & control; Clinical Trials as Topic/organization & administration; Communicable Disease Control/organization & administration; Drug Development/organization & administration; Nervous System Diseases/drug therapy; COVID-19/epidemiology; COVID-19/transmission; Humans

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Communicable Disease Control / Clinical Trials as Topic / Drug Development / COVID-19 / Nervous System Diseases Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Nat Rev Neurol Journal subject: Neurology Year: 2021 Document Type: Article Affiliation country: S41582-020-00445-w

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google